Aztreonam (injection): Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Aztreonam}} | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Overview== | ==Overview== | ||
''Aztreonam''' (Azactam®) is a synthetic monocyclic [[beta-lactam]] [[antibiotic]] (a ''[[monobactam]]'') originally isolated from ''[[Chromobacterium violaceum]]''. It was approved by the [[FDA]] in 1986. It is resistant to some [[beta-lactamase]]s, but is inactivated by extended-spectrum [[beta-lactamase]]s. | ''Aztreonam''' (Azactam®) is a synthetic monocyclic [[beta-lactam]] [[antibiotic]] (a ''[[monobactam]]'') originally isolated from ''[[Chromobacterium violaceum]]''. It was approved by the [[FDA]] in 1986. It is resistant to some [[beta-lactamase]]s, but is inactivated by extended-spectrum [[beta-lactamase]]s. | ||
==Category== | ==Category== | ||
Monobactam | Monobactam | ||
| Line 11: | Line 11: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[ | ''' [[Aztreonam description|Description]]''' | ||
'''| [[ | '''| [[Aztreonam clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Aztreonam microbiology|Microbiology]]''' | ||
'''| [[ | '''| [[Aztreonam indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Aztreonam contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Aztreonam warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Aztreonam adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Aztreonam drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[Aztreonam overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Aztreonam clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Aztreonam dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Aztreonam how supplied|How Supplied]]''' | ||
'''| [[ | '''| [[Aztreonam labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Aztreonam is similar in action to penicillin. It inhibits [[mucopeptide]] synthesis in the bacterial cell wall. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam binds the penicillin-binding proteins of [[gram-positive]] and [[anaerobic]] bacteria very poorly and is largely ineffective against them.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref> Aztreonam is bactericidal but less so than some of the [[cephalosporins]]. | Aztreonam is similar in action to penicillin. It inhibits [[mucopeptide]] synthesis in the bacterial cell wall. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam binds the penicillin-binding proteins of [[gram-positive]] and [[anaerobic]] bacteria very poorly and is largely ineffective against them.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref> Aztreonam is bactericidal but less so than some of the [[cephalosporins]]. | ||
==References== | ==References== | ||
Revision as of 23:45, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Aztreonam' (Azactam®) is a synthetic monocyclic beta-lactam antibiotic (a monobactam) originally isolated from Chromobacterium violaceum. It was approved by the FDA in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases.
Category
Monobactam
US Brand Names
AZACTAM®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Aztreonam is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them.[1] Aztreonam is bactericidal but less so than some of the cephalosporins.
References
- ↑ AHFS DRUG INFORMATION® 2006 (2006 ed ed.). American Society of Health-System Pharmacists. 2006.